Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 4/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | MMP1 | P03956 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20942743 | 0.89 | TSHR (0.40) | HSD11B1MAPK1ATMEPHX2TSHR | |
| SCHEMBL25537327 | 0.82 | MEN1 (0.44) | EPHX2TSHRL3MBTL1MEN1KMT2A | |
| SCHEMBL23464924 | 0.81 | KMT2A (0.38) | TSHRL3MBTL1GAAMEN1KMT2A | |
| SCHEMBL2430641 | 0.81 | SMYD3 (0.33) | EPHX2TSHRTP53MMP1 | |
| SCHEMBL8084486 | 0.79 | GAA (0.39) | TSHRL3MBTL1GAAMEN1KMT2A | |
| SCHEMBL8044173 | 0.79 | FKBP1A (0.41) | TSHRL3MBTL1GAAKMT2AALDH1A1 | |
| SCHEMBL12765367 | 0.78 | MAPK1 (0.40) | HSD11B1MAPK1ATMTSHRTP53 | |
| SCHEMBL13956959 | 0.77 | FKBP1A (0.44) | TSHRL3MBTL1GAAKMT2A | |
| SCHEMBL7920915 | 0.74 | POLB (0.37) | ATMTSHRL3MBTL1GAAMEN1 | |
| SCHEMBL22991258 | 0.74 | EPHX2 (0.50) | HSD11B1MAPK1ATMEPHX2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230165854-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH APJ RECEPTOR ACTIVITY | SHOUTI INC. | 2023-06-01 | — | — | US | disclosed |
| US-20230165854-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH APJ RECEPTOR ACTIVITY | SHOUTI INC. | 2023-06-01 | — | — | US | disclosed |
| US-20220125787-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH APJ RECEPTOR ACTIVITY | ANNAPURNA BIO, INC. | 2022-04-28 | — | — | US | disclosed |
| WO-2020073011-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH APJ RECEPTOR ACTIVITY | ANNAPURNA BIO, INC. (US) | 2020-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220125787-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH APJ RECEPTOR ACTIVITY | APLNR, AGTR1, AGTR2 | HSD11B1 1109/4885MAPK1 1659/4885ATM 3228/4885 |
| US-20230165854-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH APJ RECEPTOR ACTIVITY | APLNR, AGTR1, AGTR2 | HSD11B1 1109/4885MAPK1 1659/4885ATM 3228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.